
Imatinib mesylate is the first line tyrosine kinase inhibitor and the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although various cutaneous reactions to this drug are well known, but only few case reports are there documenting sweet syndrome (Ayirookuzhi et al., 2005).